HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

sergliflozin

a hypoglycemic agent that inhibits SGLT2 sodium-glucose transporter; structure in first source

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycosides: 2119
  - Glucosides: 639
    - sergliflozin: 4

Experts

1.	Dobbins, Robert L: 2 articles (06/2010 - 06/2010)
2.	Hussey, Elizabeth K: 2 articles (06/2010 - 06/2010)
3.	Layko, Debbi: 2 articles (06/2010 - 06/2010)
4.	Murray, Sharon C: 2 articles (06/2010 - 06/2010)
5.	Nunez, Derek J R: 2 articles (06/2010 - 06/2010)
6.	O'Connor-Semmes, Robin L: 2 articles (06/2010 - 06/2010)
7.	Amin, Dipti M: 1 article (06/2010)
8.	Clark, Richard V: 1 article (06/2010)
9.	Kapur, Anita: 1 article (06/2010)
10.	Kipnes, Mark S: 1 article (06/2010)

Related Diseases

1.	Overweight 06/01/2010 - "The pharmacokinetics and pharmacodynamics of sergliflozin were examined during administration of sergliflozin etabonate (500 or 1000 mg) or placebo 3 times daily (tid) for 14 days in healthy overweight or obese human volunteers (n = 18). "
2.	Hyperglycemia 06/01/2009 - "Preclinical data with SGLT2 inhibitors, such as dapagliflozin and sergliflozin, show that these compounds are highly selective inhibitors for SGLT2, have beneficial effects on the glucose utilization rate, and reduce hyperglycemia while having no hypoglycemic adverse effects. "
3.	Type 2 Diabetes Mellitus (MODY) 06/01/2010 - "The pharmacokinetics and pharmacodynamics of sergliflozin were evaluated following single oral dose administration of sergliflozin etabonate (5-500 mg) in healthy volunteers (n = 22) and patients with type 2 diabetes mellitus (n = 8). "
4.	Diabetes Mellitus 01/01/2007 - "As a representative of a new category of antidiabetic drugs, sergliflozin may provide a new and unique approach to the treatment of diabetes mellitus."

Related Drugs and Biologics

1.	Hypoglycemic Agents (Hypoglycemics)
2.	sergliflozin etabonate
3.	Glucose (Dextrose)
4.	Sodium-Glucose Transporter 2 Inhibitors
5.	dapagliflozin